Pomerantz LLP Commences Class Action Against Cytokinetics, Incorporate – CYTK
Pomerantz LLP has initiated a class action lawsuit against Cytokinetics, Inc. for alleged securities fraud and unlawful business practices. Investors who purchased Cytokinetics securities during the Class Period are encouraged to contact the firm by November 17, 2025, to be appointed as Lead Plaintiff. The lawsuit follows significant stock price declines after Cytokinetics disclosed issues regarding its New Drug Application for aficamten, including the FDA's decision not to hold an advisory committee meeting and the omission of a Risk Evaluation and Mitigation Strategy in the original filing.
NEW YORK CITY, NY / ACCESS Newswire / October 31, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Cytokinetics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until November 17, 2025, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Cytokinetics securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration ("FDA") had decided not to convene an advisory committee meeting to review the Company's New Drug Application ("NDA") for aficamten. On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten's NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy ("REMS") submitted at the FDA's request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA.
On this news, Cytokinetics' stock price fell $5.57 per share, or 12.98%, to close at $37.35 per share on May 2, 2025.
Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials.
On this news, Cytokinetics' stock price fell $2.70 per share, or 7.36%, to close at $33.97 per share on May 6, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original press release on ACCESS Newswire
